ALXN.O
Latest Trade
114.13USDChange
0.00(-0.00%)Volume
2,750,356Today's Range
-
115.2552 Week Range
-
121.50As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 114.13 |
|---|---|
Open | 114.97 |
Volume | 2,750,356 |
3M AVG Volume | 39.09 |
Today's High | 115.25 |
Today's Low | 112.72 |
52 Week High | 121.50 |
52 Week Low | 72.67 |
Shares Out (MIL) | 219.17 |
Market Cap (MIL) | 25,332.01 |
Forward P/E | 10.54 |
Dividend (Yield %) | -- |
Alexion Reports Q2 Non-Gaap Earnings Per Share $3.11
ImmunoGen Appoints Susan Altschuller As CFO
Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.
Industry
Major Drugs
Executive Leadership
David R. Brennan
Independent Chairman of the Board
Ludwig N. Hantson
Chief Executive Officer, Director
Aradhana Sarin
Executive Vice President, Chief Financial Officer
Indrani Franchini
Executive Vice President, Chief Compliance Officer
Ellen Chiniara
Executive Vice President, Chief Legal Officer. Corporate Secretary
Price To Earnings (TTM) | 30.97 |
|---|---|
Price To Sales (TTM) | 4.58 |
Price To Book (MRQ) | 2.41 |
Price To Cash Flow (TTM) | 20.97 |
Total Debt To Equity (MRQ) | 23.24 |
LT Debt To Equity (MRQ) | 22.03 |
Return on Investment (TTM) | 5.81 |
Return on Equity (TTM) | 5.41 |
The U.S. Food and Drug Administration on Saturday approved Roche's Enspryng for the central nervous system disorder neuromyelitis optica, putting the Swiss drugmaker head-to-head with Alexion's Soliris in a costly treatment area.
Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.
Alexion Pharmaceuticals <ALXN.O> has agreed to pay $21 million to resolve U.S. charges that it violated a major anti-corruption law when two of its subsidiaries paid Turkish and Russian officials for favorable treatment of its Soliris drug, the top securities regulator said...
* ALEXION PHARMACEUTICALS-ULTOMIRIS GETS MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR ADULTS,CHILDREN WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Source text for Eikon: Further company coverage:
* ALEXION ANNOUNCES PHASE 3 STUDY OF WEEKLY SUBCUTANEOUS ULTOMIRIS® (RAVULIZUMAB-CWVZ) MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:
The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:
Hedge fund Elliott Management on Tuesday publicly called on Alexion Pharmaceuticals Inc to sell itself, arguing that management's steps, including recent plans to acquire a smaller company, were leading in the wrong direction.
Activist investor Elliott Management on Tuesday revived its call for a sale of Alexion Pharmaceuticals Inc, months after the company rejected the hedge fund's earlier demand.
* ELLIOTT ADVISORS, IN LETTER TO ALEXION, SAYS BEST APPROACH FOR ALEXION IS IMMEDIATE EXPLORATION OF A SALE
* Q1 REVENUE $1.445 BILLION VERSUS REFINITIV IBES ESTIMATE OF $1.36 BILLION
* PORTOLA PHARMACEUTICALS CANCELS FIRST QUARTER 2020 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL FOLLOWING AGREEMENT TO BE ACQUIRED BY ALEXION Source text for Eikon: Further company coverage:
Alexion Pharmaceuticals Inc <ALXN.O> on Tuesday agreed to buy Portola Pharmaceuticals Inc <PTLA.O> in a $1.41 billion deal, as it looks to exploit smaller rival's blood-thinning antidote which has reached only a tiny portion of its target population.
Drugmaker Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values its smaller rival at $1.41 billion to gain access to a treatment for reversing the effects of blood thinners.
Alexion Pharmaceuticals Inc. on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values the U.S. drug developer at $1.41 billion.
* ALEXION PHARMACEUTICALS INC - DEAL FOR $18 PER SHARE IN CASH
Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome.
Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome.
* ALEXION ANNOUNCES PLANS TO INITIATE PHASE 3 STUDY OF ULTOMIRIS® (RAVULIZUMAB-CWVZ) IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19
* ALEXION PHARMACEUTICALS INC SAYS CEO LUDWIG HANTSON'S FY 2019 TOTAL COMPENSATION WAS $18.9 MILLION VERSUS $16.5 MILLION IN FY 2018 - SEC FILING
* ALEXION ANNOUNCES UPCOMING DATA PRESENTATIONS AT 72ND ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.